Pratia S.A.
- Address
- Ul. Chrzanowskiego 3 Lok 5, 81-338 Gdynia, Poland
Cardiovascular Diseases
Research at this site focuses on cardiovascular disease and related conditions, aiming to test new therapies that lower risk of heart events and improve blood pressure control.
- heart failure
- hypertension
- high cardiovascular risk
- established cardiovascular disease
- resistant hypertension
Pratia S.A. in Gdynia, Poland is running 42 trials with 19 investigators, many of which evaluate novel agents for heart health.
Digestive System Diseases
Studies target disorders of the gastrointestinal tract, especially inflammatory bowel conditions, to assess the effectiveness of emerging treatments.
- moderately to severely active ulcerative colitis
- ulcerative colitis
- inflammatory bowel disease
The centre’s investigators are evaluating oral and biologic agents that could bring faster remission for patients.
Eye Diseases
Clinical work includes trials for rare ocular disorders, seeking therapies that protect vision and reduce disease activity.
- thyroid eye disease
- ocular inflammation
Pratia S.A. leverages its multidisciplinary team to advance eye‑specific drug development.
Immune System Diseases
The site conducts research on autoimmune conditions, testing novel immunomodulators to improve symptom control and disease remission.
- psoriatic arthritis
- rheumatoid arthritis
- moderate to severe plaque psoriasis
- atopic dermatitis
- active psoriatic arthritis
Ongoing trials evaluate biologics and small molecules for better immune regulation.
Musculoskeletal Diseases
Research addresses bone and joint health, focusing on therapies that reduce pain, improve mobility, and strengthen bone density.
- chronic pain due to knee osteoarthritis
- post‑menopausal osteoporosis
- musculoskeletal pain
The investigators compare new analgesics and osteoporosis treatments to current standards.
Nervous System Diseases
Trials explore neurological conditions, aiming to prevent or lessen migraine attacks and other headache disorders.
- chronic migraine
- episodic migraine
- migraine without aura
- migraine with aura
Novel oral and injectable agents are being evaluated for their ability to reduce monthly migraine days.
Nutritional and Metabolic Diseases
The centre evaluates treatments for metabolic disorders, seeking better control of blood sugar, lipids, and body weight.
- type 2 diabetes
- obesity
- hypertriglyceridemia
- severe hypertriglyceridemia
- overweight
Studies test weekly insulin analogues, triglyceride‑lowering RNA therapies, and combination regimens with SGLT2 inhibitors.
Otorhinolaryngologic Diseases
Investigations include respiratory viruses that affect the upper airway, assessing vaccine candidates to prevent severe illness in older adults.
- respiratory syncytial virus
- human metapneumovirus
A single‑dose VLP vaccine is being tested for efficacy in adults aged 60 and above.
Respiratory Tract Diseases
The site’s work on lung conditions includes evaluating preventive strategies against viral infections that can cause serious lower‑respiratory disease.
- RSV lower respiratory tract disease
- hMPV lower respiratory tract disease
The vaccine trial aims to demonstrate protection during the first winter season after immunisation.
Skin and Connective Tissue Diseases
Research targets inflammatory skin disorders, testing new biologics and small molecules to achieve clear skin and lasting remission.
- moderate to severe atopic dermatitis
- moderate to severe plaque psoriasis
- active psoriatic arthritis
Long‑term safety and efficacy are being monitored in extension studies.
Immune System Phenomena
Studies explore the underlying immune mechanisms that drive auto‑inflammation, supporting the development of targeted therapeutics.
- immune system modulation
- cytokine inhibition
Biomarker analyses accompany clinical outcomes to clarify mode of action.
Musculoskeletal and Neural Physiological Phenomena
Trials investigate the interaction between muscle, bone, and nerve pathways, aiming to improve functional outcomes for painful musculoskeletal conditions.
- muscle‑joint signaling
- neural pain pathways
Pain reduction and functional scores are primary endpoints in these studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pratia S.A.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 3 | Unknown | 2023-06-08 | 2023-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.